Biocon targeting $1 billion revenue by FY19

11 Sep 2017 Evaluate

Biocon is targeting $1 billion revenue by the next fiscal and is betting big on small molecules and generic formulations, biosimilars, branded formulations and research services. The Bengaluru-based firm, which has been chasing the target since 2011, has identified these verticals as its key focus areas. The company had posted a revenue of Rs 4,078.7 crore in 2016-17.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.



Biocon Share Price

386.65 5.10 (1.34%)
12-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1794.30
Dr. Reddys Lab 1279.65
Cipla 1517.20
Zydus Lifesciences 929.05
Lupin 2114.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×